Results 171 to 180 of about 16,658,609 (280)

Biomaterial Techniques for Enhancing CAR-T Cell Therapy of Solid Tumours. [PDF]

Cancers (Basel)
Chilvers K, Maher J.
europepmc   +1 more source

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

Advanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu, Zhou Jing Zhang, Jing Jin, Hai Yuan Xu, Ya Xin Gu, Qian Qian Yang, You Lang Zhou   +6 more
wiley   +1 more source

CAR T-cell therapy in cancer treatment: Challenges and nursing perspectives. [PDF]

J Educ Health Promot
Sharma B, Kaur S, Sharma V.
europepmc   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025. [PDF]

Hum Vaccin Immunother
Zhang T, Wang S, Li X, Li X, Wu Y.
europepmc   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

Advanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu, Chenguang Liu, Weihong Zheng, Xiaofei Tong, Zhengwei Gui, Zonghong Lu, Sun Ieong, Lin Zhang   +7 more
wiley   +1 more source

Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy. [PDF]

Biomark Res
Wu B, Wang J, Zou Q, Cai J, Zhang Y, Zhong Q, Bai B, Liu F, Cao Y, Li P, Dai DL, Cai Q.   +11 more
europepmc   +1 more source

FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape

Advanced Science, EarlyView.
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu, Xingwei Xie, Xiaohuan Wu, Suidong Ouyang, Yang Zhou, Kang Wen, Yutong Zhong, Yuyang Chen, Handuo Wang, Yuan Gao, Ling Jiang, Hui Li, Wenli Zhao, Abai Xu, Enguang Bi   +14 more
wiley   +1 more source

The TCR in CAR T cell therapy: use it or lose it? [PDF]

Cancer Gene Ther
Liseth O, Vile R.
europepmc   +1 more source

Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy

Advanced Science, EarlyView.
Microphysiological systems are emerging as powerful human‐relevant platforms for studying neutrophil biology in cancer. Current applications of spheroids, organoids, and organ‐on‐a‐chip models are reviewed, together with future opportunities in behaviorome profiling, multi‐omics integration, personalized medicine, immune crosstalk, and multi‐organ ...
Shuai Shao, Markus Isfeld Diehl, Caroline N. Jones   +2 more
wiley   +1 more source